PMC9611196_01
Tumor 10 days after bleomycin injection.
fped-10-993450-g0001.jpg
PMC9611196_01_fped-10-993450-g0001.jpg
F1
After treatment, the patient did not experience any typical drug reactions, such as fever, vomiting, abdominal pain, or diarrhea, and was discharged the next day after the injection treatment. 10 days after treatment, the tumor became red and swollen, and the surrounding skin began to rupture (Figure 1).
Tumor after 1 week of cefmenoxime treatment.
fped-10-993450-g0002.jpg
PMC9611196_01_fped-10-993450-g0002.jpg
F2
Considering that the patient's tumor may have had a drug reaction to the infection, she was given cefmenoxime 0.15g twice a day for anti-infection; however, there was no discernible improvement, and the necrosis continued to spread (Figure 2).
Pathological section of tumor with myxoid background, round and polygonal cells (hematoxylin-eosin, original magnification x200).
fped-10-993450-g0003.jpg
PMC9611196_01_fped-10-993450-g0003.jpg
F3
The tumor was pathologically diagnosed as PMMTI (Figure 3).
immunohistochemical staining: The tumor showed diffuse immunoreactivity for (A) CD99, (C) INI1, (D) Ki-67, and (F) Vimentin, showed Partial immunoreactivity for (B) CK (AE1/AE3), showed no immunoreactivity for (E) MyoD1 (original magnification x200, for all).
fped-10-993450-g0004.jpg
PMC9611196_01_fped-10-993450-g0004.jpg
F4
ALK(-), INI1(present), CD99(+), Bcor(-), MyoD1(-), Myogenin(-), Ki-67(About 30%+), CD117(-), Synaptophysin (-), CD56 (partial +), CD30(-), Ki-67 (about 30%+), and Vimentin(+) (Figure 4). An outpatient follow-up MRI performed 1 month after the patient was discharged from the hospital, revealed no obvious tumor recurrence.